PRECIPIO INC (PRPO)
US74019L6020 - Common Stock
Overall PRPO gets a fundamental rating of 2 out of 10. We evaluated PRPO against 117 industry peers in the Health Care Providers & Services industry. PRPO has a bad profitability rating. Also its financial health evaluation is rather negative. PRPO is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
PRPO had negative earnings in the past year.
PRPO had a negative operating cash flow in the past year.
In the past 5 years PRPO always reported negative net income.
PRPO had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
PRPO has a Return On Assets of -32.35%. This is amonst the worse of the industry: PRPO underperforms 80.17% of its industry peers.
The Return On Equity of PRPO (-40.58%) is worse than 62.93% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.35% | ||
| ROE | -40.58% | ||
| ROIC | N/A |
ROA(3y)-39.03%
ROA(5y)-50.48%
ROE(3y)-50.05%
ROE(5y)-69.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRPO's Gross Margin of 39.63% is fine compared to the rest of the industry. PRPO outperforms 67.24% of its industry peers.
In the last couple of years the Gross Margin of PRPO has grown nicely.
The Profit Margin and Operating Margin are not available for PRPO so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.63% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y28%
GM growth 5Y37.55%
2. Health
2.1 Basic Checks
PRPO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRPO has more shares outstanding
Compared to 5 years ago, PRPO has more shares outstanding
PRPO has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -6.66, we must say that PRPO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of PRPO (-6.66) is worse than 86.21% of its industry peers.
PRPO has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
PRPO has a Debt to Equity ratio of 0.01. This is amongst the best in the industry. PRPO outperforms 87.07% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -6.66 |
ROIC/WACCN/A
WACC9.11%
2.3 Liquidity
PRPO has a Current Ratio of 1.17. This is a normal value and indicates that PRPO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.17, PRPO is doing worse than 61.21% of the companies in the same industry.
PRPO has a Quick Ratio of 1.05. This is a normal value and indicates that PRPO is financially healthy and should not expect problems in meeting its short term obligations.
With a Quick ratio value of 1.05, PRPO is not doing good in the industry: 61.21% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.05 |
3. Growth
3.1 Past
PRPO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.55%, which is quite impressive.
Looking at the last year, PRPO shows a very strong growth in Revenue. The Revenue has grown by 61.35%.
PRPO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 39.66% yearly.
EPS 1Y (TTM)54.55%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q132.51%
Revenue 1Y (TTM)61.35%
Revenue growth 3Y35.64%
Revenue growth 5Y39.66%
Revenue growth Q2Q81.13%
3.2 Future
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y106.24%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year65.19%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
PRPO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
With a Price/Forward Earnings ratio of 15.15, PRPO is valued correctly.
75.86% of the companies in the same industry are more expensive than PRPO, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of PRPO to the average of the S&P500 Index (21.35), we can say PRPO is valued slightly cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15.15 |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. Dividend
5.1 Amount
PRPO does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PRECIPIO INC
NASDAQ:PRPO (4/26/2024, 7:11:16 PM)
6.025
-0.15 (-2.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap8.62M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | 15.15 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -32.35% | ||
| ROE | -40.58% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 39.63% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.84
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.17 | ||
| Quick Ratio | 1.05 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)54.55%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y106.24%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)61.35%
Revenue growth 3Y35.64%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y